Press Release

<< Back
Avinger to Announce Fourth Quarter 2017 and Full Year 2017 Results on March 19th, 2018

REDWOOD CITY, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2017 after the close of trading on Monday, March 19, 2018. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 5087068. To listen to a live webcast, please visit the investor relations section of Avinger's website at:

A replay of the call will be available beginning March 19, 2018 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on March 20, 2018. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 5087068. The webcast will also be available on Avinger's website for one year following the completion of the call.

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, CA. For more information, please visit

Public Relations Contact
Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7900

Investor Contact
Matt Ferguson
Chief Business Officer and CFO
Avinger, Inc.
(650) 241-7917

Primary Logo

Avinger, Inc.